Speaking as one of KC's CYDY investors "that are s
Post# of 157634
(Total Views: 120)
Posted On: 10/04/2025 11:45:12 PM
Speaking as one of KC's CYDY investors "that are scared to death of the pps going down as many have ALL of their eggs in the CytoDyn basket", I think he makes a few good points:
1. We do need better communication and follow-up from Investor Relations; they've never answered/acknowledged any of my questions. However, I do commend Bernadette Cunningham, she got back to me very fast with inquiries on how to refer a sick young man with cancer to Cytodyn.
2. This indeed is a RACE. And at least for the last few years, maybe due to the lack of comm and often delayed study protocols and the always imminent "FDA meeting," it seems like we're getting lapped.
3. Salaries do seem pretty damn high, especially for our PPS, lack of revenue, and unmet goals. To me, this is a bad look, and so is the apparent lack of stock purchases by some on the BOD.
4. Lastly, nothing against Dr J, but I think we would better served by a proven business CEO than a research MD. Two different skillsets. And I wouldn't expect Dr J to be a master of both. A business CEO who has worked in the small biotech space, someone who has successfully guided a company through the sharks and weeds seems to give us our best chance of success.
Good Luck to all!
1. We do need better communication and follow-up from Investor Relations; they've never answered/acknowledged any of my questions. However, I do commend Bernadette Cunningham, she got back to me very fast with inquiries on how to refer a sick young man with cancer to Cytodyn.
2. This indeed is a RACE. And at least for the last few years, maybe due to the lack of comm and often delayed study protocols and the always imminent "FDA meeting," it seems like we're getting lapped.
3. Salaries do seem pretty damn high, especially for our PPS, lack of revenue, and unmet goals. To me, this is a bad look, and so is the apparent lack of stock purchases by some on the BOD.
4. Lastly, nothing against Dr J, but I think we would better served by a proven business CEO than a research MD. Two different skillsets. And I wouldn't expect Dr J to be a master of both. A business CEO who has worked in the small biotech space, someone who has successfully guided a company through the sharks and weeds seems to give us our best chance of success.
Good Luck to all!
(2)
(0)